Adult medicine · free tool
Guideline Finder
The guidelines and RACP statements your exam answers should name: what each recommends, a sentence you can write to cite it, what changed recently and the outdated answer to avoid. Quiz yourself, flip flashcards, print a cheat sheet. Free, no sign-up.
40 guidelines · 9 from RACP · 11 recently changed · checked 2026-11
You know 0%
RACP exam guideline cheat sheet · checked 2026-11 · fellowshipready.com.au
Voluntary assisted dying: the physician's stance: Statement on Voluntary Assisted Dying (RACP, November 2018). The RACP neither supports nor opposes legislation; it says legalisation is a matter for governments and that Fellows hold differing views. Where VAD is lawful, physicians should take a stance of 'critical neutrality' and keep a reflective dialogue open with competent adults near the end of life who ask about it. Patients asking about VAD should be told about palliative care; specialist palliative referral is strongly encouraged but not compulsory, and VAD is not to be treated as part of palliative care. Conscientious objection is respected, but the physician must not abandon the patient and should arrange continuing care.
Low-value care in older people (Evolve geriatric medicine): Evolve Top-5 recommendations: Australian & New Zealand Society for Geriatric Medicine (RACP Evolve / ANZSGM, Current Evolve list (accessed 2026-11)). Antipsychotics should not be the first response to behavioural and psychological symptoms of dementia. Benzodiazepines and other sedative-hypnotics should not be first-line for insomnia, agitation or delirium in older adults. Do not treat bacteriuria in older adults who lack specific urinary symptoms. Review the whole drug regimen before adding a medicine; physical restraint for delirium is a last resort only.
Low-value respiratory care (Evolve TSANZ): Evolve Top-5 recommendations: Thoracic Society of Australia and New Zealand (Adult) (RACP Evolve / TSANZ, Current Evolve list (accessed 2026-11)). Do not use D-dimer when pre-test probability of PE is high: a negative result does not exclude it, so go straight to imaging. Avoid long-term systemic corticosteroids in COPD. Avoid starting maintenance inhalers in minimally symptomatic COPD at low exacerbation risk. No routine follow-up for solid nodules under 6 mm in low-risk patients; do not use serum ACE to diagnose or monitor sarcoidosis.
Low-value care in infectious diseases (Evolve ASID): Evolve Top-5 recommendations: Australasian Society for Infectious Diseases (RACP Evolve / ASID, Current Evolve list (accessed 2026-11)). Do not treat asymptomatic bacteriuria, including with an indwelling catheter; exceptions are pregnancy and before urological procedures. Do not swab or treat leg ulcers that show no clinical signs of infection. Avoid antibiotics for upper respiratory tract infections, except sore throat in people at high risk of group A strep complications. Do not test for faecal pathogens without GI symptoms; avoid broad serology panels for fatigue without a clinical or epidemiological reason.
Low-value care in gastroenterology (Evolve GESA): Evolve Top-5 recommendations: Gastroenterological Society of Australia (RACP Evolve / GESA, Current Evolve list (accessed 2026-11)). Do not repeat colonoscopy more often than the NHMRC-endorsed surveillance intervals. FOBT has no place in investigating rectal bleeding, iron deficiency or GI symptoms; it is a screening test only. Try to step down or stop long-term PPIs to the lowest effective dose. Coeliac HLA gene testing is not a screening test; Barrett's without dysplasia on two consecutive adequate endoscopies needs no repeat for at least 3 years.
Palliative care: low-value practices (Evolve ANZSPM/AChPM): Evolve Top-5 recommendations: Australian & New Zealand Society of Palliative Medicine and Australasian Chapter of Palliative Medicine (RACP Evolve / ANZSPM and AChPM, Current Evolve list (accessed 2026-11)). Do not delay palliative care discussion or referral just because disease-directed treatment is continuing. Limit routine antipsychotic use for delirium symptoms. Do not give oxygen for breathlessness to patients who are not hypoxic. Refer to bereavement services selectively (complicated grief), and review the medication list before adding drugs in polypharmacy.
Low-value care in endocrinology (Evolve ESA): Evolve Top-5 recommendations: Endocrine Society of Australia (RACP Evolve / ESA, Current Evolve list (accessed 2026-11)). No thyroid ultrasound for abnormal thyroid function tests when the gland is clinically normal to palpation. No testosterone therapy without biochemically confirmed deficiency. Do not measure fasting or OGTT insulin to estimate insulin sensitivity. Avoid unstructured repeated glucose self-monitoring in stable T2D on non-hypoglycaemic drugs; do not check T3 to titrate thyroxine.
Low-value care in nephrology (Evolve ANZSN): Evolve Top-5 recommendations: Australian and New Zealand Society of Nephrology (RACP Evolve / ANZSN, Current Evolve list (accessed 2026-11)). Give aminoglycosides once daily, not in multiple daily doses, when kidney function is normal and stable. Oral acetylcysteine does not prevent contrast-associated AKI and should not be used for that purpose. Avoid intensive HbA1c lowering (below roughly 6.5–8%, individualised) in CKD stages 1–3 because of hypoglycaemia and mortality risk. Avoid aspirin for primary prevention in CKD stages 1–3.
Absolute cardiovascular risk assessment (Aus CVD Risk Calculator): 2023 Australian guideline for assessing and managing cardiovascular disease risk (National Heart Foundation of Australia (for Australian Chronic Disease Prevention Alliance), 2023 (MJA summary 2024)). Assess 5-year risk with the Aus CVD Risk Calculator (PREVENT-based) at 45–79 years; from 35 with diabetes; First Nations people from 30. High risk is ≥10% over 5 years, intermediate 5 to <10%, low <5%; reclassification factors include ethnicity, eGFR, uACR, severe mental illness, CAC score and family history. Moderate–severe CKD and familial hypercholesterolaemia are automatically high risk and the calculator should not be used. High risk: BP- and lipid-lowering drugs unless contraindicated; intermediate: consider; low: not routine unless BP >160/100 or total cholesterol >7.5 mmol/L.
Atrial fibrillation: stroke prevention and anticoagulation: National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 (NHFA and CSANZ, 2018). Use the sex-neutral CHA2DS2-VA score: 0 no anticoagulation, 1 consider, ≥2 recommended unless contraindicated. For non-valvular AF, prefer a NOAC (apixaban, dabigatran, rivaroxaban) over warfarin; antiplatelets are not recommended for stroke prevention. Opportunistic AF screening (pulse or single-lead ECG) from age 65. Beta-blockers or non-dihydropyridine CCBs first-line for rate control; digoxin second-line.
Heart failure with reduced ejection fraction: drug and device therapy: National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018 (NHFA and CSANZ, 2018). Echocardiography is the key test; BNP/NT-proBNP is recommended when the diagnosis is uncertain. HFrEF: ACE inhibitor (ARB if intolerant), an evidence-based beta-blocker once euvolaemic, and an MRA for all unless contraindicated. Switch ACEi/ARB to sacubitril/valsartan if symptoms persist on optimal therapy (36-hour ACEi washout); consider ivabradine if LVEF ≤35% and sinus rate ≥70. ICD for ischaemic cardiomyopathy with LVEF ≤35%; CRT for LVEF ≤35% in sinus rhythm with QRS ≥150 ms (consider 130–149 ms).
Acute coronary syndromes: diagnosis and secondary prevention: Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025 (NHFA and CSANZ, 2025 (MJA summary February 2026)). High-sensitivity troponin is built into clinical decision pathways; ECG patterns of acute coronary occlusion MI (ACOMI) beyond ST elevation are recognised. A new LDL-C target of <1.4 mmol/L with at least a 50% fall from baseline; PCSK9 inhibitors have a role in secondary prevention. Tailor DAPT duration to ischaemic and bleeding risk, with a step-down approach for patients also needing a DOAC. Beta-blockers are recommended with LV dysfunction; benefit is not shown with preserved EF after early angiography, or beyond 12 months.
Hypertension: diagnosis and first-line treatment: Guideline for the diagnosis and management of hypertension in adults — 2016 (National Heart Foundation of Australia, 2016). Confirm raised clinic BP (≥140/90) with ambulatory or home BP monitoring. First-line options are ACE inhibitor or ARB, calcium channel blocker or thiazide diuretic; never combine ACEi with ARB. Beta-blockers are not first-line for uncomplicated hypertension. Target <140/90 generally; <120 systolic (automated office BP) may suit selected high-risk patients with close monitoring.
Type 2 diabetes: glucose-lowering therapy choice: Australian Type 2 Diabetes Glycaemic Management Algorithm (Australian Diabetes Society, September 2026). Metformin is usual first-line unless contraindicated; sulfonylureas are not preferred as the first add-on because of hypoglycaemia. Add an SGLT2 inhibitor in people with CVD, multiple CV risk factors or kidney disease; a GLP-1 RA is the alternative if an SGLT2i cannot be used. HbA1c target commonly ≤53 mmol/mol (7.0%), individualised; review at 3 months and reconsider agents that lower HbA1c by <0.5%. Use only one incretin agent (not DPP-4i with GLP-1 RA).
SGLT2 inhibitors before surgery: euglycaemic DKA: ADS/ADEA/ANZCA/NZSSD Alert: Periprocedural diabetic ketoacidosis with SGLT2 inhibitor use (Australian Diabetes Society with ADEA, ANZCA and NZSSD, Alert update July 2022). For procedures needing ≥1 day in hospital or bowel preparation, withhold the SGLT2i for at least 3 days (the 2 days before plus the day of the procedure). For day procedures without bowel prep (e.g. gastroscopy), withhold on the day only. Measure blood ketones; ketones >1.0 mmol/L with base excess below −5 indicates DKA even if glucose is normal (euDKA if glucose <14). Postpone non-urgent surgery if ketosis with acidosis is present.
Osteoporosis: who to treat and denosumab cessation: 2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age (RACGP and Healthy Bones Australia, 2024 (3rd edition; MJA summary 2025)). A minimal-trauma fracture after 50 implies osteoporosis; treat if T-score ≤ −2.5, or −1.5 to −2.5 with FRAX major osteoporotic risk ≥20% and/or hip ≥3%. Very high risk (recent fracture, T-score < −3.0, fracture on therapy) warrants specialist referral for anabolic therapy (romosozumab or teriparatide) followed by an antiresorptive. Denosumab should not be stopped or delayed (>4 months) without transition to a bisphosphonate, because of rebound vertebral fractures. Reconsider bisphosphonates after 5–10 years if T-score is > −2.5 and there are no recent fractures.
Driving after a seizure (Austroads): Assessing Fitness to Drive for commercial and private vehicle drivers (AP-G56) (Austroads and National Transport Commission, 2022 edition (effective 22 June 2022)). Private drivers: generally no driving for at least 6 months after a first unprovoked seizure, and 12 months seizure-free for epilepsy (default standard). Commercial drivers have much longer seizure-free periods (years) and EEG requirements; unconditional commercial licences are generally not regained. A crash or loss of control caused by a seizure reverts the driver to the default standard. The patient has the legal duty to notify the licensing authority; the doctor advises and documents, and may report if public safety is at risk.
Acute ischaemic stroke: thrombolysis and thrombectomy: Australian and New Zealand Living Clinical Guidelines for Stroke Management (Stroke Foundation, Living guideline (Chapter 3 updated 2024)). IV thrombolysis with tenecteplase or alteplase within 4.5 hours of last known well for eligible patients; alteplase up to 9 hours (or wake-up) with perfusion mismatch. Endovascular thrombectomy for ICA or proximal M1 occlusion, including 6–24 hours after last known well when CT perfusion or MRI shows salvageable tissue. Aspirin plus clopidogrel started within 24 hours for about 3 weeks after minor ischaemic stroke or high-risk TIA. LDL-C target below 1.8 mmol/L after ischaemic stroke; PFO closure for under-60s when the PFO is the likely cause.
CKD: staging and kidney-protective therapy: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (KDIGO, 2024). Stage by cause, GFR (G1–G5) and albuminuria (A1–A3). SGLT2i for T2D with CKD and eGFR ≥20; also for CKD with eGFR ≥20 and uACR ≥20 mg/mmol, or heart failure, regardless of diabetes. ACEi or ARB for CKD with severely increased albuminuria (A3), and for diabetes with A2 or A3. Statin (or statin/ezetimibe) for adults ≥50 with CKD not on dialysis.
COPD: diagnosis and exacerbation management (Australia): COPD-X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease (Lung Foundation Australia (endorsed by TSANZ), Version 2.78 (December 2025)). Confirm COPD with spirometry: post-bronchodilator FEV1/FVC <0.7. Structured as C-O-P-D-X: Confirm, Optimise function, Prevent deterioration, Develop a plan, manage eXacerbations. In exacerbations, target SpO2 88–92%, give systemic corticosteroids for about 5 days, and use NIV for hypercapnic respiratory acidosis. Pulmonary rehabilitation improves symptoms and function and should be offered, including after an exacerbation.
Asthma in adults: reliever and starting treatment: Australian Asthma Handbook (National Asthma Council Australia, 2025 edition (revised, current online version)). Every adult and adolescent with asthma should have inhaled corticosteroid-containing treatment. Preferred approach: ICS-formoterol as the reliever, taken as needed, with or without daily maintenance doses (anti-inflammatory reliever). Alternative approach: daily ICS or ICS-LABA maintenance with a separate SABA reliever. SABA is now the alternative, not the standard, reliever.
COPD: international strategy (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD 2026 Report) (Global Initiative for Chronic Obstructive Lung Disease, 2026 Report). Patients are grouped A, B or E by symptoms and exacerbation history to guide initial therapy. Escalation should be considered after even one moderate exacerbation, aiming for a low disease activity state. Initial treatment for treatment-naive patients is now separated from follow-up adjustments in revised algorithms. Vaccination advice now covers RSV as well as influenza; new sections on disease activity and biologics.
Delirium: screening, prevention and avoiding antipsychotics: Delirium Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2021). Screen for cognitive impairment with a validated tool on presentation (within 24 hours) in people ≥65, or ≥45 for Aboriginal and Torres Strait Islander people. Use multicomponent non-drug prevention strategies for those at risk. Antipsychotics are not recommended to treat delirium; reserve short, low-dose use for imminent risk of harm when non-drug measures fail; avoid benzodiazepines. Identify and treat underlying causes and communicate the delirium episode at transfer of care.
Sepsis: recognition and time to antimicrobials (Australia): Sepsis Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2022). Seven quality statements, starting with 'Could it be sepsis?' and ending with survivorship care after discharge. With suspected sepsis and infection-related organ dysfunction, give the first antimicrobial dose within 60 minutes of recognition (sooner with shock). Take blood cultures first but do not let them delay antimicrobials; where infection is uncertain and there is no shock, start within 3 hours if concern persists. Review antimicrobials within 48 hours of the first dose.
Septic shock: resuscitation and vasopressors: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 (Society of Critical Care Medicine and European Society of Intensive Care Medicine, 2021). Do not use qSOFA alone as a screening tool (strong recommendation against, compared with SIRS, NEWS or MEWS). Antimicrobials within 1 hour for possible septic shock or high likelihood of sepsis. Suggest 30 mL/kg IV crystalloid within 3 hours for hypoperfusion (weak), preferably balanced crystalloids (weak). Noradrenaline is the first-line vasopressor, targeting MAP 65 mmHg.
Alcohol withdrawal and Wernicke's prevention: Guidelines for the Treatment of Alcohol Problems (University of Sydney (Haber & Riordan), commissioned by the Australian Government, 4th edition (2021)). All patients in alcohol withdrawal should receive thiamine to prevent Wernicke's encephalopathy. Give thiamine before any carbohydrate load such as IV glucose where feasible, otherwise as soon as possible. Poor nutrition: 300 mg IM or IV daily for several days, then oral; suspected Wernicke's: higher parenteral doses (500 mg three times daily) with specialist advice. Benzodiazepines (e.g. diazepam) guided by a withdrawal scale remain the mainstay of withdrawal treatment.
Paracetamol overdose: acetylcysteine regimen: Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand (Australian and New Zealand poisons centres and clinical toxicologists (MJA), 2020 (MJA 212(4))). Two-bag acetylcysteine: 200 mg/kg over 4 hours then 100 mg/kg over 16 hours (fewer reactions than the old three-bag regimen). If the paracetamol level is more than double the nomogram line, double the second bag; discuss with a toxicologist at triple. Modified-release ingestion ≥10 g or ≥200 mg/kg: start acetylcysteine and give the full course regardless of level. Activated charcoal within 2 hours (4 hours if >30 g) in a cooperative adult; continue acetylcysteine if paracetamol >10 mg/L or ALT >50 and rising.
Anaphylaxis: acute management: ASCIA Guidelines: Acute Management of Anaphylaxis (Australasian Society of Clinical Immunology and Allergy, 2024 (updated July 2024)). IM adrenaline 1:1000, 0.01 mg/kg to a maximum of 0.5 mg, into the outer mid-thigh; repeat after 5 minutes if no response. Lay the patient flat (or sitting with legs out if breathing is hard); do not let them stand or walk. Antihistamines do not treat airway or circulatory compromise; corticosteroids are not first-line and never replace adrenaline. Observe for at least 4 hours after the last adrenaline dose; longer for higher-risk patients.
Bowel cancer screening: starting age: Clinical practice guidelines for the prevention, early detection and management of colorectal cancer: population screening and risk-based screening recommendations (Cancer Council Australia, 2023 update (released 21 November 2023)). Average-risk population screening with an immunochemical FOBT every 2 years now starts at 45 rather than 50 (to 74). Targeted screening advice for people with a family history was revised by risk category. FOBT is a screening test for asymptomatic people; symptomatic patients need colonoscopy. The National Bowel Cancer Screening Program lowered its eligible age to 45 after these recommendations.
Lung cancer screening eligibility (NLCSP): National Lung Cancer Screening Program (Australian Government Department of Health, Disability and Ageing, Program commenced 1 July 2025). Eligible: age 50–70, no symptoms of lung cancer, current smoker or quit within the past 10 years. Smoking history of at least 30 pack-years. Screening uses low-dose CT, requested by a healthcare provider and recorded on the National Cancer Screening Register. Symptomatic patients need diagnostic investigation, not screening.
Hypertension in pregnancy: aspirin, targets and drugs: SOMANZ Hypertension in Pregnancy Guideline 2023 (Society of Obstetric Medicine of Australia and New Zealand, 2023). High-risk women: aspirin 150 mg daily (bedtime suggested) started before 16 weeks and stopped between 34 weeks and birth. Calcium supplementation if dietary intake is under 1 g/day. Treat chronic or gestational hypertension to SBP ≤135 and DBP ≤85; oral labetalol, methyldopa or nifedipine first-line. sFlt-1/PlGF ratio ≤38 can help rule out pre-eclampsia over 1–4 weeks; review within 1 week of discharge and at 3–6 months postpartum.
Venous thromboembolism: treatment and duration: New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism (THANZ, 2019 (MJA 210(5))). Oral factor Xa inhibitors are preferred over dabigatran or warfarin for proximal DVT and PE; DOACs are avoided in pregnancy and breastfeeding (use LMWH). Surgery- or trauma-provoked proximal DVT/PE: at least 3 months; unprovoked: 3–6 months then decide on extended therapy. Cancer-associated VTE: at least 6 months; LMWH, or rivaroxaban/edoxaban case by case given higher bleeding risk. Routine thrombophilia testing is not indicated; occult cancer screening is clinical assessment plus age-appropriate screening, not routine CT.
Red cell transfusion thresholds in medical patients: Patient Blood Management Guidelines: Module 3 – Medical (National Blood Authority (NHMRC-approved), 2012 (under review; remains current)). Do not decide on transfusion by Hb alone; assess the clinical picture. Hb <70 g/L: transfusion may reduce mortality and is likely appropriate; 70–100 g/L: not associated with lower mortality, decide on symptoms; >100 g/L: usually inappropriate. If transfusing, give a single unit then reassess. Identify and treat iron deficiency (IV iron in heart failure improves function); avoid routine ESAs in cancer-related anaemia.
Gout: urate-lowering therapy: 2020 American College of Rheumatology Guideline for the Management of Gout (American College of Rheumatology, 2020). Treat to target: start low, titrate up, aim for serum urate <6 mg/dL (about 0.36 mmol/L). Allopurinol is first-line, including in CKD. Anti-inflammatory prophylaxis (colchicine, NSAID or prednisolone) for at least 3–6 months when starting ULT. Test HLA-B*5801 before allopurinol in people of Southeast Asian (e.g. Han Chinese, Korean, Thai) or African American descent.
Rheumatoid arthritis: DMARD strategy: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update (EULAR, 2022 update). Start methotrexate as first DMARD, with short-term glucocorticoids tapered and stopped as quickly as possible. Treat to target: sustained remission or low disease activity; adjust if not improved by 3 months or not at target by 6 months. Further therapy is stratified by individual risk factors after inadequate response. JAK inhibitors only after considering cardiovascular and malignancy risk factors; prefer a biologic when those risks are present.
Low-value care in neurology (Evolve ANZAN): Evolve Top-5 recommendations: Australian and New Zealand Association of Neurologists (RACP Evolve / ANZAN, Current Evolve list (accessed 2026-11)). No carotid imaging for simple syncope without focal neurological symptoms. No brain imaging for non-acute primary headache (migraine, tension-type) with a normal neurological examination. Avoid opioids for migraine except in rare circumstances. Avoid epidural steroids for back pain without radicular symptoms; do not routinely recommend surgery for asymptomatic carotid stenosis >50%.
Smoking cessation pharmacotherapy: Supporting smoking cessation: A guide for health professionals (RACGP, 2nd edition, revised 2021). Offer brief advice to every smoker and referral to Quitline-type call-back counselling. First-line drugs with behavioural support: varenicline, combination NRT (patch plus oral form) or bupropion; varenicline and combination NRT are more effective than bupropion. NRT is safe in stable cardiovascular disease, with caution after recent MI, unstable angina, severe arrhythmia or recent stroke. Nicotine vaping products may be considered after failed first-line therapy, with shared decision-making about unknown long-term risks.
Dementia: cognitive enhancers and BPSD: Clinical Practice Guidelines and Principles of Care for People with Dementia (NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People (Cognitive Decline Partnership Centre), 2016 (NHMRC-approved)). Cholinesterase inhibitors for mild to moderate Alzheimer's disease; could be considered in Lewy body, Parkinson's, vascular or mixed dementia; not for MCI. Memantine can be considered, including with a cholinesterase inhibitor in moderate to severe Alzheimer's. Non-drug approaches come first for BPSD; antipsychotics are not usually used for mild–moderate symptoms because of stroke and death risk. If an antipsychotic is used for severe distressing symptoms, review every 4–12 weeks; trial an SSRI (best evidence citalopram) for agitation and treat pain.
Neutropenic fever: definition and first-hour care: Neutropenic fever: patient evaluation, risk assessment and immediate management (eviQ ID 123) (eviQ (Cancer Institute NSW), Version 7). Defined as temperature ≥38.0 °C with ANC <0.5 × 10⁹/L, or <1.0 × 10⁹/L and expected to fall below 0.5 within 48 hours. With sepsis or septic shock, IV antibiotics within 1 hour of presentation; take blood cultures first but do not delay. Without systemic compromise or MDRO risk, piperacillin-tazobactam 4.5 g IV 6-hourly (cefepime an alternative). MASCC score ≥21 is low risk and may suit oral outpatient treatment; ≤20 is high risk.
Germline cancer genetic testing threshold: eviQ cancer genetics consensus statement: scope of genetic testing protocols (ID 3672) (eviQ (Cancer Institute NSW) cancer genetics reference committees, Version 4 (last reviewed August 2024)). Germline testing is recommended when there is at least a 10% chance of finding an actionable pathogenic (class 4 or 5) variant. A result is actionable if it changes management, surveillance or risk-reducing surgery for the patient or relatives, or has reproductive implications. Panels may include lower-probability genes if findings would be actionable. Protocols are aimed at clinical genetics services and familial cancer centres.
Summaries are written in our own words from each guideline's official page and are for exam study, not clinical use. Guidelines change: check the source before you rely on it.
Try 20 free questions.
RACP-style questions, marked with a reason for every option. Free account, no card.
Also free: Anatomy Scroller · RACP exam guides